A detailed history of Nichols & Pratt Advisers LLP transactions in Abb Vie Inc. stock. As of the latest transaction made, Nichols & Pratt Advisers LLP holds 27,235 shares of ABBV stock, worth $5.29 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
27,235
Previous 27,940 2.52%
Holding current value
$5.29 Million
Previous $5.09 Million 8.18%
% of portfolio
0.32%
Previous 0.35%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$154.79 - $180.76 $109,126 - $127,435
-705 Reduced 2.52%
27,235 $4.67 Million
Q1 2024

Apr 29, 2024

SELL
$159.82 - $182.1 $9,908 - $11,290
-62 Reduced 0.22%
27,940 $5.09 Million
Q4 2023

Feb 07, 2024

BUY
$137.6 - $154.97 $4,128 - $4,649
30 Added 0.11%
28,002 $4.34 Million
Q3 2023

Nov 09, 2023

BUY
$133.59 - $154.65 $53,035 - $61,396
397 Added 1.44%
27,972 $4.17 Million
Q2 2023

Aug 02, 2023

BUY
$132.51 - $164.9 $29,814 - $37,102
225 Added 0.82%
27,575 $3.72 Million
Q1 2023

May 03, 2023

SELL
$144.61 - $166.54 $107,011 - $123,239
-740 Reduced 2.63%
27,350 $4.36 Million
Q4 2022

Feb 03, 2023

BUY
$138.31 - $165.87 $92,667 - $111,132
670 Added 2.44%
28,090 $4.54 Million
Q3 2022

Nov 01, 2022

BUY
$134.21 - $153.93 $110,723 - $126,992
825 Added 3.1%
27,420 $3.68 Million
Q2 2022

Aug 04, 2022

BUY
$137.62 - $174.96 $10,321 - $13,122
75 Added 0.28%
26,595 $4.07 Million
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $23,096 - $28,656
175 Added 0.66%
26,520 $4.3 Million
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $112,801 - $142,726
1,050 Added 4.15%
26,345 $3.57 Million
Q3 2021

Nov 01, 2021

BUY
$106.4 - $120.78 $213,332 - $242,163
2,005 Added 8.61%
25,295 $2.76 Million
Q2 2021

Aug 09, 2021

BUY
$105.21 - $117.21 $149,924 - $167,024
1,425 Added 6.52%
23,290 $2.62 Million
Q1 2021

May 11, 2021

BUY
$102.3 - $112.62 $1.03 Million - $1.13 Million
10,075 Added 85.45%
21,865 $2.37 Million
Q4 2020

Feb 08, 2021

BUY
$80.49 - $108.67 $462,012 - $623,765
5,740 Added 94.88%
11,790 $1.26 Million
Q3 2020

Nov 10, 2020

BUY
$85.91 - $100.83 $60,137 - $70,581
700 Added 13.08%
6,050 $530,000
Q1 2020

Apr 24, 2020

BUY
$64.5 - $97.79 $70,950 - $107,569
1,100 Added 25.88%
5,350 $407,000
Q4 2019

Feb 07, 2020

SELL
$72.13 - $90.25 $155,079 - $194,037
-2,150 Reduced 33.59%
4,250 $376,000
Q3 2019

Nov 07, 2019

BUY
$62.98 - $75.72 $6,298 - $7,572
100 Added 1.59%
6,400 $484,000
Q2 2019

Aug 05, 2019

BUY
$65.7 - $83.98 $13,140 - $16,796
200 Added 3.28%
6,300 $458,000
Q1 2019

Apr 30, 2019

SELL
$77.14 - $90.79 $862,425 - $1.02 Million
-11,180 Reduced 64.7%
6,100 $492,000
Q4 2018

Feb 08, 2019

SELL
$77.85 - $96.01 $171,270 - $211,222
-2,200 Reduced 11.29%
17,280 $1.59 Million
Q3 2018

Nov 05, 2018

SELL
$88.91 - $98.84 $53,346 - $59,304
-600 Reduced 2.99%
19,480 $1.84 Million
Q2 2018

Jul 27, 2018

SELL
$89.78 - $106.23 $22,445 - $26,557
-250 Reduced 1.23%
20,080 $1.86 Million
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $41,404 - $55,444
-450 Reduced 2.17%
20,330 $1.92 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $17,912 - $19,642
-200 Reduced 0.95%
20,780 $2.01 Million
Q3 2017

Nov 08, 2017

SELL
$69.85 - $89.22 $34,925 - $44,610
-500 Reduced 2.33%
20,980 $1.87 Million
Q2 2017

Aug 08, 2017

BUY
N/A
21,480
21,480 $1.56 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Nichols & Pratt Advisers LLP Portfolio

Follow Nichols & Pratt Advisers LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nichols & Pratt Advisers LLP , based on Form 13F filings with the SEC.

News

Stay updated on Nichols & Pratt Advisers LLP with notifications on news.